면역독소 시장 - 세계 산업 규모, 점유율, 동향, 기회, 예측 : 제품별, 용도별, 최종사용자별, 지역별 및 경쟁(2021-2031년)

The Global Immunotoxins Market is projected to expand from USD 178.86 Million in 2025 to USD 293.58 Million by 2031, reflecting a CAGR of 8.61%. Immunotoxins are engineered chimeric proteins that combine a targeting moiety, such as a ligand or monoclonal antibody, with a potent bacterial or plant-derived toxin intended to selectively bind to and destroy diseased cells. The market is primarily driven by the increasing global incidence of cancer and the growing demand for precision oncology treatments that offer reduced off-target toxicity compared to systemic chemotherapy, while advancements in recombinant DNA technology are enabling the creation of less immunogenic constructs with improved therapeutic windows. According to the American Cancer Society, approximately 66,890 new cases of leukemia are expected to be diagnosed in the United States in 2025, highlighting the critical need for effective interventions in hematological malignancies that these agents frequently target.

Despite this positive outlook, the market encounters a significant obstacle regarding safety, particularly the risk of vascular leak syndrome. This severe adverse event involves fluid leakage from capillaries, which complicates patient management and necessitates limits on the maximum tolerated dose. Such toxicity issues can impede regulatory approval processes and restrict the broader commercial adoption of immunotoxin therapies.

Market Driver

The escalating prevalence of cancer and hematological malignancies serves as the primary catalyst for the Global Immunotoxins Market, generating urgent demand for potent biological therapies capable of eliminating resistant cells. As global incidence rates rise, healthcare systems are prioritizing the adoption of targeted agents that provide superior efficacy compared to conventional treatments. This trend is underscored by the International Agency for Research on Cancer (IARC), which reported in its 'Global Cancer Burden Estimates' in February 2024 that there were an estimated 20 million new cancer cases worldwide in 2022, emphasizing the increasing disease burden that requires advanced interventions. To facilitate the discovery of novel modalities like immunotoxins, substantial public funding is being directed toward oncology research; for instance, the National Cancer Institute received a consolidated budget of $7.22 billion in 2024 to support a wide range of cancer research and training, creating an environment favorable for developing next-generation protein-based therapeutics.

Market growth is further accelerated by the expansion of the clinical pipeline and regulatory approvals, as biopharmaceutical companies successfully advance novel immunotoxin constructs through late-stage trials. Developers are applying recombinant DNA technology to engineer constructs with enhanced stability and reduced immunogenicity, directly addressing historical safety barriers such as vascular leak syndrome. A significant clinical breakthrough was highlighted by Medicenna Therapeutics in June 2024; in results presented at ASCO, the immunotoxin Bizaxofusp demonstrated a median overall survival of 13.5 months in patients with recurrent glioblastoma, representing an 88% improvement over the external control arm. Such successes validate the therapeutic potential of immunotoxins, encouraging continued investment and paving the way for faster regulatory pathways to commercialization.

Market Challenge

The risk of vascular leak syndrome remains a primary impediment to the commercial expansion of the global immunotoxins market. This severe adverse event often requires strict limitations on dosage, preventing the therapeutic agent from reaching the optimal concentration necessary to effectively eradicate large tumor masses. Consequently, pharmaceutical developers encounter increased regulatory scrutiny and extended clinical trial timelines, as demonstrating a favorable risk-benefit ratio becomes increasingly difficult. These safety concerns frequently relegate immunotoxins to third-line or salvage settings rather than first-line treatments, which significantly reduces the addressable patient population and diminishes investor confidence in late-stage pipeline candidates.

This toxicity limitation directly hinders market penetration in high-incidence indications where these agents could otherwise have a major impact. While immunotoxins are heavily investigated for hematological cancers such as non-Hodgkin lymphoma, safety hurdles prevent their widespread deployment. According to the American Cancer Society, approximately 80,350 new cases of non-Hodgkin lymphoma are projected to be diagnosed in the United States in 2025. The inability to safely administer immunotoxins to this substantial patient base, due to risks like vascular leak syndrome, effectively caps revenue potential and slows the overall adoption rate of these biologic therapies.

Market Trends

The global immunotoxins market is being reshaped by an expansion into solid tumor therapeutic applications, shifting the modality beyond its traditional success in hematological malignancies toward difficult-to-treat indications such as glioblastoma. Developers are increasingly prioritizing late-stage clinical programs that utilize direct delivery systems to bypass the systemic toxicity often associated with bacterial toxins. This strategic pivot is demonstrated by significant resource allocation toward registrational trials designed to validate these agents in solid tissue environments. For example, Medicenna Therapeutics reported in its 'First Quarter Fiscal 2026 Financial Results' in August 2025 that the company held a cash balance of $20.5 million to actively support partnering efforts and the Phase 3 readiness of its lead immunotoxin, Bizaxofusp, for the treatment of recurrent glioblastoma.

Simultaneously, the integration of AI in immunotoxin design and discovery is emerging as a critical trend to address historical limitations regarding immunogenicity and off-target binding. By using machine learning algorithms, researchers can now predict protein structures and optimize antibody-toxin interfaces with unprecedented accuracy, facilitating the creation of next-generation constructs with improved safety profiles. As noted by Chemistry World in the November 2025 article 'AI-designed antibodies target antigens with atomic precision,' a new AI-guided process utilizing the RFdiffusion model successfully produced antibodies that bind to specific antigen sites with atomic-level precision, a technological breakthrough expected to accelerate the development of highly specific and less immunogenic immunotoxin payloads.

Key Market Players

• Creative Biolabs, Inc.
• List Biological Labs, Inc.
• The Native Antigen Company
• Bio-Techne Corporation
• Abcam Limited
• Cayman Chemical Company
• Merck KGaA
• Enzo Biochem Inc.
• Santa Cruz Biotechnology In
• Quadratech Diagnostics Ltd

Report Scope

In this report, the Global Immunotoxins Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Immunotoxins Market, By Product

• Diptheria Toxin
• Anthrax Based Toxins
• Pseudomonas Exotoxin
• Others

Immunotoxins Market, By Application

• Biomedical Research
• Therapy Development

Immunotoxins Market, By End User

• Pharmaceutical & Biotechnology Companies
• CROs & CMOs
• Academic & Research Institutes

Immunotoxins Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Immunotoxins Market.

Available Customizations:

Global Immunotoxins Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Immunotoxins Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Diptheria Toxin, Anthrax Based Toxins, Pseudomonas Exotoxin, Others)
  • 5.2.2. By Application (Biomedical Research, Therapy Development)
  • 5.2.3. By End User (Pharmaceutical & Biotechnology Companies, CROs & CMOs, Academic & Research Institutes)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Immunotoxins Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Application
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Immunotoxins Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Immunotoxins Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Immunotoxins Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By End User

7. Europe Immunotoxins Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Application
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Immunotoxins Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By End User
  • 7.3.2. France Immunotoxins Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Immunotoxins Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Immunotoxins Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Immunotoxins Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By End User

8. Asia Pacific Immunotoxins Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Application
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Immunotoxins Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By End User
  • 8.3.2. India Immunotoxins Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Immunotoxins Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Immunotoxins Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Immunotoxins Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By End User

9. Middle East & Africa Immunotoxins Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Application
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Immunotoxins Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End User
  • 9.3.2. UAE Immunotoxins Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End User
  • 9.3.3. South Africa Immunotoxins Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End User

10. South America Immunotoxins Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Application
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Immunotoxins Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End User
  • 10.3.2. Colombia Immunotoxins Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End User
  • 10.3.3. Argentina Immunotoxins Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Immunotoxins Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Creative Biolabs, Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. List Biological Labs, Inc.
• 15.3. The Native Antigen Company
• 15.4. Bio-Techne Corporation
• 15.5. Abcam Limited
• 15.6. Cayman Chemical Company
• 15.7. Merck KGaA
• 15.8. Enzo Biochem Inc.
• 15.9. Santa Cruz Biotechnology In
• 15.10. Quadratech Diagnostics Ltd

16. Strategic Recommendations

17. About Us & Disclaimer